David H. Talbot
Blood test software that detects stage 0 cancer tumors and T1 diabetes 5 years before onset has 1Q announcement potential. Sanofi\'s recent launch of TZIELD targeted therapy for T1D is just the start.
- Role
- Senior Advisor at Otraces, Inc
- Location
- New York, NY, US
- LinkedIn followers
- 500 followers
About David H. Talbot
Former I-I Poll HC analyst for more than a decade at leading firms always looking for the next big HC megatrend. After a 9 year recent sabbatical from writing reports and extensive tire kicking and DD, I believe the merger digital HC, breakthroughs in early disease detection and rise of targeted therapy revolution is starting to come to fruition and I thrilled to be the first senior analyst driving the research coverage bus!
Experience
Senior Advisor
Nov 2015 — Present · Sykeville, MD
I have extensive buy-side and side HC research experience. AstraZeneca and Sanofi are current leaders in the targeted therapy field with record prospects and FDA approval momentum. Meanwhile, the near-term outlook for early detection and screening tests remains unclear. Current Grail cutbacks could impact other companies in the ctDNA liquid biopsy pursuing early detection/screening tests. Illumina and The Broad Institute of MIT and Harvard have formed a partnership to significantly revamp and revise the company’s business strategy- we believe strong evidence that OTraces, Inc. is well-positioned.
Education
Brown University
Bachelor of Arts - BA
Brown University
AB
1955 — 1959
Kellogg Graduate School of Management
MBA
1961 — 1963
Skills
- Venture Capital
- Biotechnology
- Analysis
- Healthcare Industry Megatrends
- Healthcare Industry
- Mergers & Acquisitions
- Investment Banking
Find verified contacts for anyone on LinkedIn
Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.
Free plan included · No credit card required
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.